BriaCell presents preclinical data from Phase 3 study of Bria-IMT

BriaCell (BCTX) Therapeutics is presenting clinical data from the Phase 3 study of its product candidate, Bria-IMT, in metastatic breast cancer supporting the use of specific biomarkers to predict patients’ clinical response to Bria-IMT treatments. Biomarkers could be utilized to predict and provide better patient outcomes, including response rates and survival benefits with BriaCell’s novel Bria-IMT regimen. “We are very pleased with our early Phase 3 biomarker data highlighting their importance as important tools in BriaCell’s fight against metastatic breast cancer, a difficult to treat and deadly disease,” stated Dr. William V. Williams, BriaCell’s President & CEO.